Status: Automated market-move research draft
MANKIND • NSE • F&O Stock
MANKIND PHARMA LIMITED traded at ₹2,545.00, +4.49% versus the previous close of ₹2,435.60. Latest market data: 29 Sep 2026 • 03:15 PM IST.
- The stock is +4.49% at ₹2,545.00.
- Likely reason: Stock-specific buying and volume surge
- Approximate traded value is ₹500.81 crore.
- It is -3.67% from its 52-week high and +33.27% from its 52-week low.
- The stock is being compared with Nifty Pharma alongside the Nifty 50.
MANKIND PHARMA LIMITED Share Price Today – Market Snapshot
Why Is MANKIND PHARMA LIMITED Share Price Rising Today?
Mankind Pharma Limited shares advanced notably in today's session, gaining 4.49% to close at ₹2,545.00. The stock opened at ₹2,440.40 and touched an intraday high of ₹2,557.60, operating near the upper bound of its daily price band. Trading activity spiked significantly, with volume surging to 2.81 times its 5-day average and 4.17 times its 20-day average, accompanied by a healthy delivery percentage of 35.35%.
In relative terms, Mankind Pharma outperformed the broader market and outpaced its sectoral benchmark. While the benchmark Nifty index slipped by 0.28%, the Nifty Pharma sector gained a modest 0.64%, reflecting strong buying interest centered specifically on Mankind against a flat-to-negative broader market backdrop.
On the corporate and news front, the company recently announced the resignation of the statutory auditors of its material wholly-owned subsidiary, Bharat Serums and Vaccines Limited, following earlier board consent for its voluntary liquidation and integration into the parent company. While these administrative restructuring updates provide backdrop context, today's sharp price momentum and high trading volume appear primarily driven by strong stock-specific accumulation and buying interest.
medium confidence
- Intraday gain of 4.49% with price closing near the day's high of ₹2,557.60
- Volume surged to 4.17 times the 20-day average
- Outperformed Nifty's decline of 0.28% and Nifty Pharma's gain of 0.64%
Performance Context
Cash-Market Activity
| Today’s Volume | 1,967,833 |
|---|---|
| 5-Day Avg. Volume | 699,166 |
| 20-Day Avg. Volume | 472,398 |
| Volume vs 20-Day Avg. | 4.17x |
| Delivery Quantity | 697,782 |
| Delivery % | 35.35% |
| Number of Trades | 84,454 |
Derivative-Market Activity
| Near-Month Futures | ₹2,443.90 |
|---|---|
| Cash Reference | ₹2,435.65 |
| Premium / Discount | ₹8.25 (+0.34%) |
| Change in Premium | ₹10.25 |
| Futures Volume | 3,991 |
| Volume vs Previous Session | 0.80x |
| Open Interest | 227,750 |
| OI vs Previous Session | 0.22x |
Ownership & Transaction Activity
Promoter Pledge / Encumbrance
Completion of Realignment of Security Cover in respect of Non-ConvertibleDebentures and Consequent Release of Pledged Shares of Bharat Serums andVaccines Limited
Source: NSE corporate filing
Recent Ownership / Shareholding Disclosure
- Promoter group submitted compliance disclosures under Regulation 31(4) of SEBI SAST Regulations confirming zero encumbrances for FY ending March 31, 2026.
- Ramesh Juneja, Rajeev Juneja, and Sheetal Arora are listed among the key promoter and promoter group entities.
Source: NSE corporate disclosure. Only factual ownership/shareholding details extracted from the filing are shown.
WittyTrades Data Insight
Price Position: The stock is near the upper end of the day’s trading range.
Move From Open: +4.29%.
Intraday Range: 4.81% of the previous close.
5-Day Performance: +2.62%; 20-Day Performance: +8.00%.
Latest Company Developments
Relative Performance
| MANKIND PHARMA LIMITED | +4.49% |
|---|---|
| Nifty 50 | -0.28% |
| Nifty Pharma | +0.64% |
| Vs Nifty 50 | +4.77% |
| Vs Sector | +3.85% |
Technical Context
| Price | ₹2,545.00 |
|---|---|
| Day High / Low | ₹2,557.60 / ₹2,440.40 |
| 52-Week High | ₹2,642.00 |
| 52-Week Low | ₹1,909.70 |
| 5-Day Return | +2.62% |
| 20-Day Return | +8.00% |
What Should Traders and Investors Watch Next?
- Progress and regulatory approvals regarding the voluntary liquidation and integration of Bharat Serums and Vaccines Limited
- Commercialization updates on the newly in-licensed insulin products in the anti-diabetic segment
- Sustained delivery volumes and price stability above key moving averages
- Upcoming financial results and management commentary on chronic therapy margins
Catalyst note: No single same-day catalyst was officially announced to directly trigger today's surge, which appears driven by strong institutional or retail accumulation and volume expansion.
Frequently Asked Questions
What is the likely reason for today’s move?
The stock rallied 4.49% on significantly elevated trading volume (over 4x its 20-day average), outperforming both the broader Nifty and Nifty Pharma indices. While recent corporate restructuring updates regarding its subsidiary provide context, the sharp price movement reflects strong underlying buying interest.
Is trading volume elevated?
Today’s volume is 1,967,833. The latest 20-day average available is 472,398, equivalent to about 4.17x of the recent average.
What does the derivatives market show?
The latest official NSE F&O report is summarised in the Derivative-Market Activity box above.
Before acting on this stock
Consult your own investment adviser before acting on any security. If you are interested in stock research or other available research categories, review the WittyTrades subscription plans and research segments.
Market data, exchange filings, company disclosures and reputable business-media reports are collected automatically and summarised for investor context. Material facts are cross-checked where possible; price data may be delayed and a cited development should not be assumed to be the sole cause of a market move unless the evidence supports that conclusion.
Article by: WittyTrades Research Desk
Investments in securities markets are subject to market risks. Read all related documents carefully before investing.
Registration granted by SEBI, membership of a supervisory body and certification from NISM do not guarantee performance of the intermediary or provide any assurance of returns to investors.
This article is intended for informational and educational purposes and should not be treated as personalised investment advice or a recommendation to buy, sell or hold any security.
Market data may be delayed and readers should independently verify current prices and disclosures before taking investment decisions.